Navigation Links
Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Date:1/28/2009

PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets. Genpharm also received final FDA approval for its ANDA for a separate Lamotrigine product, Lamotrigine Tablets Chewable Dispersible (CD).

Mylan Pharmaceuticals' and Genpharm's ANDAs were approved for the 25 mg, 100 mg, 150 mg and 200 mg strengths of the generic version of GlaxoSmithKline's Lamictal(R) Tablets. This product had annual U.S. sales of approximately $2.5 billion for the 12 months ending Sept. 30, 2008, for the same strengths according to IMS Health.

Genpharm's ANDA was approved for the 5 mg and 25 mg strengths of the generic version of GlaxoSmithKline's Lamictal(R) CD Tablets. This product had annual U.S. sales of approximately $91 million for the 12 months ending Sept. 30, 2008, for the same strengths according to IMS Health.

These products are used for the treatment of epilepsy and for maintenance treatment of bipolar I disorder. Mylan will distribute both products immediately and under the Mylan Pharmaceuticals label.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit '/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
2. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
3. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
5. Mylan Announces Move to NASDAQ Stock Market
6. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
7. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
8. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
11. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... - Even while being dragged to its destruction ... fires away, sending signals that thwart the development ... reported in an early online publication at ... often encountered by tumors, the epidermal growth factor ... an international team led by scientists at The ...
(Date:5/23/2013)... May 23, 2013 The Rottenstein Law ... firm, has created the Tylenol Lawsuit Information Center at ... Tylenol users and those who are considering filing lawsuits. ... to potentially cause severe liver damage, according to a ... In the “safety communication,” the FDA warned consumers ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... 2013 Jeanne Ettelson, president of ... popular and only free OCD support group in Chicago. ... for OCD sufferers, the group is lead by psychologists ... This allows group participants to learn accurate information ... Prevention. , “Participants in Beyond OCD’s support group ...
(Date:5/23/2013)... 23 (HealthDay News) -- Schools should ensure that ... activity each day to support their health and ... report. Although previous studies show 60 ... health and development, it,s estimated that only about ... this recommendation, according to the report from the ...
Breaking Medicine News(10 mins):Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... Experts on the Battle Against H1N1 , WASHINGTON, Oct. 8 ... of the House and Senate, the Aspen Institute and TIME magazine ... on what the looming changes will mean for the American people. ... Banquet and Conference Center, at the Reserve Officers Association, One Constitution ...
... Oct. 8 Health by Design of San Antonio, TX, ... individuals, has recently appointed Omar Rodriguez as Executive Vice President, ... in the health care arena, Rodriguez assumes a newly created ... its unique approach to medical care. His first area of ...
... , SILVER SPRING, Md., Oct. 8 The ... Food and Drug Administration, has filed a complaint for ... Calif., seeking to stop the company from manufacturing, producing, ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , The complaint ...
... have just learned they,re in the running for the 2009 Hutch ... one of whom will go on to receive the prestigious Hutch ... finalists for the 45th annual Hutch Award are: , Jonny ... Los Angeles Angels of Anaheim Mark Lowe, Seattle Mariners ...
... , The Prem Rawat Foundation,s grant to St. John of Jerusalem ... LOS ANGELES, Oct. 8 A $25,000 grant by The Prem ... (SJJEH) to provide eye care for 30,000 children in an area ... the West. Over 50% of the people in the Palestinian Territories, ...
... Australia and U.S., most patients recovering, death rate same ... -- Potentially foreshadowing the U.S. experience this fall and ... just gone through their flu season report "substantial" traffic ... H1N1 swine flu infections. , Because winter in the ...
Cached Medicine News:Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 2Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 3Health News:Health Care Industry Leader Joins Health by Design Executive Team 2Health News:FDA Takes Enforcement Action Against Ready-to-Eat Sandwich Manufacturer 2Health News:Ten Finalists Chosen for Hutch Award(R) 2Health News:TPRF Gives US$25,000 to Help Provide Eye Care for Children in Palestinian Territories 2Health News:Swine Flu May Bring Surge in Hospitalizations 2Health News:Swine Flu May Bring Surge in Hospitalizations 3
(Date:5/23/2013)... -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), ... and commercialization of novel bile acid therapeutics to treat ... announced that Mark Pruzanski , MD, ... Deutsche Bank Securities 38th Annual Health Care Conference in ... 2013 at 4:10 p.m. ET. About Intercept ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, ... announced today that it will present new results ... an industry conference sponsored by the PML Consortium ... Idec).  JC polyomavirus (JCV) is the causative agent ... tyrosine kinase inhibitor in an extended release formulation, ...
(Date:5/23/2013)... 23, 2013  PAREXEL International Corporation (NASDAQ: ... at the Jefferies Healthcare Conference in New York.  ... Chief Financial Officer, will be making a presentation on ... Monday, June 3, 2013. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2PAREXEL International To Present At Jefferies Healthcare Conference 2
... March 20, 2012  OriGene Technologies today announced the ... and extensively validated monoclonal antibodies under the UltraMAB™ ... antibodies which are exclusively developed by OriGene for ... products available on the market that have been ...
... YORK, March 20, 2012 Reportlinker.com announces that ... its catalogue: The Outlook ... http://www.reportlinker.com/p0192645/The-Outlook-for-Medical-Devices-in-Central-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Facility The ... total market of 303 million people and a ...
Cached Medicine Technology:OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies 2The Outlook for Medical Devices in Central Asia 2The Outlook for Medical Devices in Central Asia 3The Outlook for Medical Devices in Central Asia 4